In a report released today, James McIlree from Dawson James maintained a Buy rating on 22nd Century (XXII – Research Report), with a price target of $1.00. The company’s shares closed last Friday at $0.38.
According to TipRanks, McIlree is ranked #8426 out of 8435 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 22nd Century with a $1.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.32 and a one-year low of $0.34. Currently, 22nd Century has an average volume of 2.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
22nd Century Group, Inc. is a plant biotechnology company, which engages in the development of technology that will allow to increase or decrease the level of nicotine and nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. Its products include X-22, modified risk cigarettes, spectrum government research cigarettes, magic 0 and magic 2, moonlight, red sun, variable nicotine-level research cigarettes, and verfola. The company was founded on September 12, 2005 and is headquartered in Clarence, NY.
Read More on XXII:
- 22nd Century Announces 1-for-15 Reverse Stock Split
- 22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet
- 22nd Century announces production of VLN homogenized tobacco leaf sheet
- 22nd Century announces VLN products launch in Nevada
- 22nd Century prices $5.3M registered direct offering at $0.47 per share
